Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Enzyme-Linked Immunosorbent Assay01:33

Enzyme-Linked Immunosorbent Assay

17.0K
In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen.  Enzyme-substrate reaction allows the antigen to be visualized or...
17.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acceptability and appropriateness of remote monitoring and self-administered pulse oximetry among COVID-19 patients in Honduras: a mixed-methods study.

Primary health care research & development·2026
Same author

A multiplexed, systems-based approach for prediction of antibody neutralization breadth for soluble human receptors.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Biological foundation models illuminate annotation blind spots in evolutionarily divergent genomes.

bioRxiv : the preprint server for biology·2026
Same author

A glycan-based adjuvant expands the breadth and duration of protection of mRNA-based vaccines.

Nature immunology·2026
Same author

Improving cholera vaccination impact through advances in gut mucosal immunology: outcomes of a 2025 expert consultation.

Vaccine·2026
Same author

Breast milk antibody Fc signatures track with HIV transmission during breastfeeding in ART-naïve mothers.

iScience·2026
Same journal

Optimized intracellular flow cytometry panel enables CD4 and CD8 T cell cytokine profiling in Syrian hamsters.

Journal of immunological methods·2026
Same journal

Isosulfan blue sentinel lymph node biopsy enables reliable lymph node harvest and multicolor flow cytometry in mice.

Journal of immunological methods·2026
Same journal

Type-specific antibody detection of herpes simplex virus types 1&2 (HSV-1&2) in fingerstick blood at point-of-care sites by a rapid and sensitive lateral flow immunochromatographic assay.

Journal of immunological methods·2026
Same journal

Development of chimeric DGP-IgG antibodies as quality control for celiac disease diagnosis.

Journal of immunological methods·2026
Same journal

Stepwise single-cell-resolved deep immunophenotyping pipeline to characterise immune heterogeneity and functionality in health and disease.

Journal of immunological methods·2026
Same journal

Performance evaluation of Meso Scale Discovery (MSD) quantitative serological assays for detection of binding (IgG, IgA, IgM) and ACE2 inhibitory antibody levels for SARS-CoV-2.

Journal of immunological methods·2026
See all related articles

Related Experiment Video

Updated: Dec 12, 2025

A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System
07:08

A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System

Published on: April 6, 2021

5.3K

SARS-CoV-2-specific ELISA development.

Vicky Roy1, Stephanie Fischinger1, Caroline Atyeo1

  • 1Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, United States of America.

Journal of Immunological Methods
|August 12, 2020
PubMed
Summary
This summary is machine-generated.

A new quantitative ELISA assay can accurately detect antibodies to SARS-CoV-2, the virus that causes COVID-19. This test provides a reliable method for assessing past infection and immunity levels in populations.

More Related Videos

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
10:25

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

5.1K
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.2K

Related Experiment Videos

Last Updated: Dec 12, 2025

A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System
07:08

A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System

Published on: April 6, 2021

5.3K
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
10:25

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

5.1K
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.2K

Area of Science:

  • Immunology
  • Virology
  • Diagnostic Assays

Background:

  • Managing COVID-19 spread requires accurate diagnosis and understanding of population-level immune response.
  • Current genomic tests for SARS-CoV-2 detect viral RNA but have a limited detection window.
  • There is a critical need for tests that can identify past exposure and infection beyond the period of active viral shedding.

Purpose of the Study:

  • To develop and qualify a quantitative immunoassay for detecting antibodies against SARS-CoV-2.
  • To establish a high-throughput diagnostic tool for assessing population immunity to COVID-19.
  • To provide a reliable method for defining exposure and immunity levels post-SARS-CoV-2 infection.

Main Methods:

  • Development and qualification of a quantitative enzyme-linked immunosorbent assay (ELISA).
  • Evaluation of assay characteristics for high-throughput sample analysis.
  • Assessment of antibody detection as a durable marker of infection and exposure.

Main Results:

  • A qualified quantitative ELISA assay for SARS-CoV-2 antibodies was successfully developed.
  • The assay demonstrated characteristics suitable for high-throughput sample analysis.
  • The test provides a quantitative measure of both exposure and immunity to SARS-CoV-2.

Conclusions:

  • The developed ELISA assay offers a robust tool for diagnosing past SARS-CoV-2 infection.
  • This quantitative assay enables accurate assessment of population-level immunity.
  • The test facilitates a better understanding of the acquired immune response to COVID-19.